At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 24, 2026 at 08:31 ET
Entrada Therapeutics is holding a shareholder meeting to vote on the election of directors, approval of the 2025 annual compensation program, and ratification of auditors. The filing is a definitive additional materials document, which is routine for an annual meeting.
- Filing is a Definitive Additional Materials (DEFA14A) for an annual shareholder meeting.
- Vote includes election of directors, approval of 2025 annual compensation program, and ratification of auditors.
- No activist campaign or dissident filing; this is a routine management filing.
- Recent insider activity shows minimal selling ($32K over 30 days).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access